Update of FDA Preliminary Public Health Notification*: Guidant VENTAK PRIZM® 2 DR and CONTAK RENEWAL® Implantable Cardioverter Defibrillators
This is an archived document and is no longer current information.
October 13, 2005
This is an update of our July 14, 2005 Preliminary Public Health Notification (PPHN) about malfunctions occurring with Guidant’s PRIZM® 2 and CONTAK RENEWAL® implantable cardioverter defibrillator (ICD) devices, which were the subjects of a Class I recall announced by the Food and Drug Administration (FDA) on July 1, 2005.
The affected devices are:
- VENTAK PRIZM® 2 DR, Model 1861, manufactured on or before April 16, 2002
- CONTAK RENEWAL®, Model H135, manufactured on or before August 26, 2004
- CONTAK RENEWAL® 2, Model H155, manufactured on or before August 26, 2004
We are providing this update because Guidant has informed us that six (6) additional clinical occurrences (of which FDA has 4 confirmed reports) exhibiting this failure mode worldwide have been reported for the Contak Renewal® and Renewal® 2 devices since our July 14, 2005 PPHN, for a total of 21 clinical failures, including 3 patient deaths, worldwide as of October 7, 2005. You should take these failures into account as you continue to follow the patients who retain either device.
No additional clinical failures have been reported for the Ventak Prizm® 2DR since our July 14, 2005 PPHN. Guidant informed FDA and the clinical community that there were a total of 28 clinical failures, including 1 patient death, worldwide as of June 17, 2005, with no new reports since that date. Therefore, our previous recommendations remain unchanged for patients implanted with the Prizm® 2 DR.
In addition to design changes previously instituted by Guidant, FDA recently approved a modification to the Prizm 2 DR and Contak Renewal devices that should further reduce the likelihood of this failure mode occurring in newly manufactured devices. This modification involved replacing the insulating material on the feedthrough wires with a different insulating material that has better degradation properties. This change does not affect devices already implanted prior to the fix.
Summary of July 14, 2005 Preliminary Public Health Notification
Damage to the device’s circuitry due to the inappropriate shorting of a defibrillation pulse back into the circuit allowed by degraded insulation can result in the inability to deliver the required shock during episodes of arrhythmia. This malfunction could lead to a serious, life-threatening event. At the time of the July 14, 2005 PPHN, at least two deaths attributable to this failure mode had been reported. We recommended replacement of any device that had demonstrated the failure mode. We recommended that, in the absence of demonstrated failure, the decision about replacement be made by the patient in consultation with his or her physician and should be based on the patient’s condition, medical history, and other pertinent factors. We also provided recommendations for follow-up of patients who retain the device. Because there are no signs of impending device failure, and there is no test that predicts whether or when any particular device will fail, FDA concluded that there is insufficient evidence to support the value of a commanded shock as a means to check for pending failures.
Reporting Adverse Events to FDA
FDA requires hospitals and other user facilities to report deaths and serious injuries associated with the use of medical devices. If you suspect that a reportable adverse event was related to the use of a Guidant ICD, you should follow the reporting procedure established by your facility. Prompt reporting of adverse events can improve FDA’s understanding of and ability to communicate the risks associated with devices and assist in the identification of potential future problems.
We also encourage you to report adverse events related to ICDs that do not meet the requirements for mandatory reporting. You can report these directly to the device manufacturer. You can also report to MedWatch, the FDA’s voluntary reporting program. You may submit reports to MedWatch by phone at 1-800-FDA-1088; by FAX at 1-800-FDA-0178; by mail to MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857-9787. Consumers can also report directly to MedWatch.
If you have questions about this Notification, please contact FDA's Division of of Small Manufacturers, International and Consumer Assistance (DSMICA) by e-mail at email@example.com or by phone at 1-800-638-2041 or 301-796-7100
FDA Medical Device Public Health Notifications are available on the Internet. You can also be notified through email each time a new Public Health Notification is added to our web page. To subscribe, visit: http://service.govdelivery.com/service/subscribe.html?code=USFDA_39.
Daniel G. Schultz, MD
Center for Devices and Radiological Health
Food and Drug Administration
* CDRH Preliminary Public Health Notifications are intended to quickly share device-related safety information with healthcare providers when the available information and our understanding of an issue are still evolving. We will revise them as new information merits and so encourage you to check this site for updates.